LabCorp Clinical Trials Selected as a Preferred Provider for Global Central Laboratory Services by Bristol-Myers Squibb

  LabCorp Clinical Trials Selected as a Preferred Provider for Global Central
  Laboratory Services by Bristol-Myers Squibb

Business Wire

BURLINGTON, N.C. -- April 1, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE:LH) today
announced that LabCorp Clinical Trials has been selected as a preferred
provider for full-service global central laboratory services and biomarker
testing by Bristol-Myers Squibb Company (NYSE: BMY).

The five-year agreement builds on a long-standing partnership between the two
companies during which LabCorp’s global central lab, biomarker and specialty
testing capabilities have supported various Bristol-Myers Squibb early and
late-stage clinical development programs.

“We are excited to expand our relationship with Bristol-Myers Squibb to
provide a more flexible and integrated approach to laboratory testing services
in support of their innovative clinical development pipeline,” said Dr. Mark
Brecher, LabCorp’s Chief Medical Officer.

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its Specialty Testing Group:
The Center for Molecular Biology and Pathology, National Genetics Institute,
ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink
Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc,
Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox,
and Endocrine Sciences. LabCorp conducts clinical trials testing through its
LabCorp Clinical Trials division. LabCorp clients include physicians,
government agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our company, visit our Web site

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.


Investor/Media Contact:
Stephen Anderson, 336-436-5076
Company Information:
Press spacebar to pause and continue. Press esc to stop.